Src kinases as targets for B cell acute lymphoblastic leukaemia therapy.

Abstract

The participation of Src kinases in the induction of BCR-ABL-induced B cell acute lymphoblastic leukaemia (B-ALL), but not chronic myeloid leukaemia (CML), demonstrates cell type-specific signalling in Philadelphia chromosome-positive (Ph+) leukaemias. Different therapeutic strategies are therefore needed for B-ALL and CML. Activation of Src kinases is independent of BCR-ABL kinase activity for activation. Thus, Src kinases provide a mechanism for resistance to the BCR-ABL kinase inhibitors and potential targets for B-ALL therapy. Simultaneous targeting of both BCR-ABL and Src kinases may benefit human B-ALL patients. Leukaemic stem cells may exist in Ph+ B-ALL, and eradication of this group of cells would provide a curative method for this disease.

• Authors: Shaoguang Li
• Journal: Expert opinion on therapeutic targets (Expert Opin Ther Targets) Vol. 9 Issue 2 Pg. 329-41 (Apr 2005) ISSN: 1744-7631 [Electronic] England
• PMID: 15934919 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antineoplastic Agents
• Protein Kinase Inhibitors
• src-Family Kinases

Topics

• Animals
• Antineoplastic Agents (administration & dosage, therapeutic use)
• Burkitt Lymphoma (drug therapy, enzymology)
• Drug Delivery Systems (methods)
• Humans
• Protein Kinase Inhibitors (administration & dosage, therapeutic use)
• src-Family Kinases (antagonists & inhibitors, metabolism)